"id","uuid:ID","text","instanceType","label","description","name"
"Objective_1","5685fb23-841a-4259-8d06-12e0a28883af","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective","","Main objective","OBJ1"
"Objective_2","53452c79-cf64-4af1-b004-2ebd2c53d3de","To document the safety profile of the xanomeline TTS.","Objective","","Safety","OBJ2"
"Objective_3","d42fa815-001a-41dc-b1f7-140a99a356de","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective","","Behaviour","OBJ3"
